Longeveron Inc. (LGVN) Stock Analysis & Investment Frameworks
Longeveron Inc. (LGVN) stock analysis on Invetso. Review Longeveron Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Longeveron Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Longeveron Inc. Key Financial Metrics
- Market Cap: $4.35M
- Revenue: $1.20M
- ROE: -223.19%
- ROIC: -201.13%
- Dividend Yield: N/A
About Longeveron Inc.
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Longeveron Inc. Investment Frameworks
Invetso analyzes Longeveron Inc. (LGVN) across the following frameworks:
- Longeveron Inc. 10Y Growth Potential
- Longeveron Inc. Scenario Analysis
- Longeveron Inc. Risks & Opportunities
- Longeveron Inc. Economic Moat
- Longeveron Inc. Business Model
- Longeveron Inc. Management
- Longeveron Inc. SWOT Analysis
- Longeveron Inc. Porter's 5 Forces
- Longeveron Inc. PESTLE Analysis
- Longeveron Inc. ESG Analysis